These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. More on DSMBs. Rosenblatt M; Kim PS N Engl J Med; 2011 May; 364(19):1879-80. PubMed ID: 21561365 [No Abstract] [Full Text] [Related]
6. Preliminary observations from preliminary trial results: have we finally had enough? Taylor AJ; Nissen SE Circ Cardiovasc Qual Outcomes; 2008 Sep; 1(1):54-7. PubMed ID: 20031788 [No Abstract] [Full Text] [Related]
7. At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy. Hamilton-Craig I; Kostner K; Colquhoun D; Woodhouse S Heart Lung Circ; 2009 Oct; 18(5):343-6. PubMed ID: 19586799 [TBL] [Abstract][Full Text] [Related]
8. Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. Green A; Ramey DR; Emneus M; Iachina M; Stavem K; Bolin K; McNally R; Busch-Sørensen M; Willenheimer R; Egstrup K; Kesäniemi YA; Ray S; Basta N; Kent C; Pedersen TR Am J Cardiol; 2014 Nov; 114(10):1518-22. PubMed ID: 25267716 [TBL] [Abstract][Full Text] [Related]
9. Premature release of data from clinical trials of ezetimibe. Califf RM; Harrington RA; Blazing MA N Engl J Med; 2009 Aug; 361(7):712-7. PubMed ID: 19675335 [No Abstract] [Full Text] [Related]
10. Hypercholesterolaemia: Clarifications from adverse drug reactions agency. Cox A BMJ; 2008 Sep; 337():a1669. PubMed ID: 18796483 [No Abstract] [Full Text] [Related]
11. In brief: Ezetimibe/simvastatin (Vytorin) in chronic kidney disease. Med Lett Drugs Ther; 2012 Jan; 54(1381):4. PubMed ID: 22233589 [No Abstract] [Full Text] [Related]
12. Reasons to be cautious about cholesterol lowering drugs. Struthers M BMJ; 2008 Sep; 337():a1493. PubMed ID: 18768557 [No Abstract] [Full Text] [Related]
13. Increased epistaxis with use of ezetimibe/simvastatin. Shah B; McAllister A; Davidson TM Ann Pharmacother; 2009 Sep; 43(9):1545. PubMed ID: 19671801 [No Abstract] [Full Text] [Related]
14. Rosiglitazone and the FDA. Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586 [No Abstract] [Full Text] [Related]
15. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. Hiatt WR; Kaul S; Smith RJ N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603 [No Abstract] [Full Text] [Related]
16. FDA committee urges tight restrictions on rosiglitazone. Roehr B BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290 [No Abstract] [Full Text] [Related]
19. Analyses of cancer data from three ezetimibe trials. Nissen SE N Engl J Med; 2009 Jan; 360(1):86-7; author reply 87. PubMed ID: 19118312 [No Abstract] [Full Text] [Related]
20. The Avandia debate: an unhappy conclusion. Bloomgarden Z; Handelsman Y J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505 [No Abstract] [Full Text] [Related] [Next] [New Search]